Company Sector

Infectious Disease

Infectious Disease includes companies developing antivirals, antibiotics, vaccines, and other programs aimed at preventing or treating viral, bacterial, or fungal infections. It is a broad category that can span both commercial public health products and early-stage pipeline assets.

Why watch Infectious Disease

This page combines a company index, a watch action, and the newest relevant feed items in one place so readers can monitor a biotech theme without scanning each company one by one.

Latest Infectious Disease news

The latest feed items from companies currently grouped under Infectious Disease.

01
2026-06-30 12:45 EST
VIRIDogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
Source: Virios Therapeutics
02
2026-06-25 13:46 EST
AVIRAtea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Source: Atea
03
2026-06-25 13:46 EST
AVIRAtea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026
Source: Atea
04
2026-06-25 13:46 EST
VIRIDogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
Source: Virios Therapeutics
05
2026-06-25 13:46 EST
VIRIDogwood Therapeutics Announces First Quarter 2026 Financial Results
Source: Virios Therapeutics
06
2026-06-25 13:46 EST
AVIRAtea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline
Source: Atea
07
2026-06-25 13:46 EST
AVIRAtea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Source: Atea
08
2026-06-25 13:46 EST
VIRIDogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
Source: Virios Therapeutics
09
2026-06-25 13:46 EST
VIRIDogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
Source: Virios Therapeutics
10
2026-06-25 13:46 EST
VIRIDogwood Therapeutics Reports Third Quarter 2025 Financial Results
Source: Virios Therapeutics
11
2026-06-25 13:46 EST
VIRIDogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025
Source: Virios Therapeutics
12
2026-06-25 13:46 EST
VIRIDogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045
Source: Virios Therapeutics
13
2026-06-25 13:46 EST
VIRIDogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
Source: Virios Therapeutics
14
2026-06-25 13:46 EST
VIRIDogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
Source: Virios Therapeutics
15
2026-06-25 13:46 EST
VIRIDogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
Source: Virios Therapeutics
16
2026-06-25 13:46 EST
VIRIDogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Source: Virios Therapeutics
17
2026-06-25 13:46 EST
VIRIDogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
Source: Virios Therapeutics
18
2026-06-25 13:46 EST
VCNXVaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain
Source: Vaccinex
19
2026-06-25 13:46 EST
VCNXVaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
Source: Vaccinex
20
2026-06-25 13:46 EST
VCNXVaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
Source: Vaccinex

View all latest news

Companies in Infectious Disease

9 companies tagged with Infectious Disease.

AUVI

Applied UV

ARGS

Argos

AVIR

Atea

CDTX

Cidara Therapeutics

COCP

Cocrystal Pharma

MRNA

Moderna, Inc.

POAI

Predictive Oncology

VCNX

Vaccinex

VIRI

Virios Therapeutics

Frequently Asked Questions

What does the Infectious Disease sector include?

How many companies are currently tagged with Infectious Disease?

9 companies are currently grouped under Infectious Disease on BioPharmSignal.

Which companies are most visible in the Infectious Disease group right now?

AUVI, ARGS, AVIR, CDTX are among the companies currently shown on this sector page.

How can I watch news for Infectious Disease?

Use the Watch button on this page to subscribe to Infectious Disease headlines and related company updates through your BioPharmSignal saved filters.

What kinds of updates usually appear for Infectious Disease?

The livefeed typically surfaces company press releases, clinical readouts, FDA and regulatory updates, partnerships, financings, and commercialization developments tied to companies in Infectious Disease.